Demand shift appears to complicate Cristália-Takeda plant deal scrutiny in Brazil
By Maria Júlia Baumert ( June 16, 2026, 21:55 GMT | Comment) -- Cristália’s planned acquisition of Takeda’s pharmaceutical plant in Jaguariúna in Brazil is raising questions about how easily pharmaceutical companies could shift outsourced manufacturing away from the facility, highlighting a layer of complexity behind what otherwise appeared to be a straightforward asset transaction.Cristália's planned acquisition of Takeda Pharmaceuticals' manufacturing facility in Jaguariúna in Brazil is raising questions about how easily pharmaceutical companies could shift outsourced manufacturing away from the plant, highlighting a layer of complexity behind what otherwise appeared to be a straightforward asset transaction....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.